News | Renal Denervation | January 14, 2025

Medtronic Receives CMS National Coverage Analysis for Renal Denervation System

National coverage analysis is the first-of-its kind for a minimally invasive, interventional treatment for high blood pressure.


Jan. 13, 2025 — Medtronic plc recently announced that the Centers for Medicare & Medicaid Services (CMS) is opening a national coverage analysis (NCA) on renal denervation, a process that will allow the agency to review and develop a national Medicare coverage policy for renal denervation procedures for patients with hypertension. This national coverage analysis was initiated by CMS in response to Medtronic's request to support Medicare beneficiary access to the Symplicity Spyral renal denervation (RDN) system, used in the Symplicity blood pressure procedure.

"Hypertension is a global health epidemic that impacts a wide variety of patients," said Jason Weidman, senior vice president and president of the Coronary and Renal Denervation business within the Cardiovascular Portfolio at Medtronic. "As the leader in developing a minimally invasive treatment option for hypertension, Medtronic has been closely engaged with CMS to establish a national coverage pathway for Symplicity Spyral. We appreciate CMS' efforts in creating new pathways to expedite access to breakthrough technologies like Symplicity Spyral and look forward to our continued partnership in developing a national coverage policy."

CMS' action follows Medtronic's work with the agency to pilot the framework for the Transitional Coverage for Emerging Technologies (TCET) pathway to establish coverage for the Symplicity Spyral renal denervation system, a U.S. FDA-approved breakthrough device. As referenced in the CMS tracking sheet, the expected completion date for the national coverage analysis is October 11, 2025. Until a national coverage determination is put into effect, Symplicity blood pressure procedures will continue to be evaluated for coverage based on medical necessity for individual Medicare patients.  

For more information on Medtronic, visit www.Medtronic.com


Related Content

News | Renal Denervation

Jan. 13, 2025 — Medtronic recently announced that the Centers for Medicare & Medicaid Services (CMS) is opening a ...

Home January 27, 2025
Home
News | Renal Denervation

November 20, 2023 — Medtronic plc, a global leader in healthcare technology, announced that the United States Food and ...

Home November 20, 2023
Home
News | Renal Denervation

August 21, 2023 — The Society for Cardiovascular Angiography & Interventions (SCAI) has released a position statement on ...

Home August 21, 2023
Home
News | Renal Denervation

March 2, 2023 — ReCor Medical, Inc. and its parent company, Otsuka Medical Devices Co., Ltd. announced that primary ...

Home March 02, 2023
Home
News | Renal Denervation

December 9, 2020 — SoniVie, an Israeli company developing the Therapeutic Intra-Vascular Ultrasound (TIVUS) System to ...

Home December 09, 2020
Home
News | Renal Denervation

June 26, 2020 – New data from the Global SYMPLICITY Registry (GSR) showed that renal denervation (RDN) with the ...

Home June 26, 2020
Home
News | Renal Denervation

April 1, 2020 — Three months after undergoing renal denervation (RDN), patients with untreated high blood pressure had ...

Home April 01, 2020
Home
News | Renal Denervation

April 1, 2020 — Three months after undergoing renal denervation (RDN), patients with untreated high blood pressure had ...

Home April 01, 2020
Home
News | Renal Denervation

May 23, 2019 – Investigators unveiled late-breaking clinical data from a first-of-its-kind physician sponsored clinical ...

Home May 23, 2019
Home
Feature | Renal Denervation

May 30, 2018 — Despite the best efforts of clinicians to manage hypertension, it continues to increase and is now ...

Home May 30, 2018
Home
Subscribe Now